Deciphera Pharmaceuticals (DCPH) Cut to “Hold” at BidaskClub

Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Monday.

A number of other research firms have also commented on DCPH. B. Riley lowered their price target on shares of Deciphera Pharmaceuticals from $52.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday, May 9th. Zacks Investment Research lowered shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. Finally, ValuEngine raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has an average rating of “Buy” and an average price target of $41.14.

Deciphera Pharmaceuticals traded up $1.87, reaching $26.83, during mid-day trading on Monday, Marketbeat.com reports. 137,586 shares of the company’s stock were exchanged, compared to its average volume of 146,715. Deciphera Pharmaceuticals has a one year low of $24.95 and a one year high of $26.32. The firm has a market cap of $813.55 million and a price-to-earnings ratio of -8.97. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.12 and a current ratio of 11.12.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, May 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). sell-side analysts anticipate that Deciphera Pharmaceuticals will post -2.69 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. ArrowMark Colorado Holdings LLC increased its holdings in Deciphera Pharmaceuticals by 15.1% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 231,760 shares of the company’s stock valued at $5,254,000 after buying an additional 30,475 shares during the period. Hudson Bay Capital Management LP increased its holdings in Deciphera Pharmaceuticals by 10.0% in the 4th quarter. Hudson Bay Capital Management LP now owns 220,000 shares of the company’s stock valued at $4,987,000 after buying an additional 20,000 shares during the period. Emerald Advisers Inc. PA increased its holdings in Deciphera Pharmaceuticals by 37.6% in the 4th quarter. Emerald Advisers Inc. PA now owns 482,626 shares of the company’s stock valued at $10,941,000 after buying an additional 131,886 shares during the period. American International Group Inc. bought a new position in Deciphera Pharmaceuticals in the 4th quarter valued at about $126,000. Finally, Quantitative Systematic Strategies LLC bought a new position in Deciphera Pharmaceuticals in the 4th quarter valued at about $288,000. 48.20% of the stock is currently owned by hedge funds and other institutional investors.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply